Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis.
Identifieur interne : 003360 ( PubMed/Corpus ); précédent : 003359; suivant : 003361Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis.
Auteurs : Marie Robin ; Federica Giannotti ; Eric Deconinck ; Mohamad Mohty ; Mauricette Michallet ; Guillermo Sanz ; Patrice Chevallier ; Jean-Yves Cahn ; Faezeh Legrand ; Montserrat Rovira ; Jakob Passweg ; Jorge Sierra ; Stephanie Nguyen ; Natacha Maillard ; Ibrahim Yakoub-Agha ; Werner Linkesch ; Paul Cannell ; Magda Marcatti ; Jacques-Olivier Bay ; Yves Chalandon ; Nicolaus Kröger ; Eliane Gluckman ; Vanderson Rocha ; Eduardo Olavarria ; Annalisa RuggeriSource :
- Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation [ 1523-6536 ] ; 2014.
English descriptors
- KwdEn :
- Cord Blood Stem Cell Transplantation (adverse effects), Cord Blood Stem Cell Transplantation (methods), Female, Fetal Blood, Hematopoietic Stem Cell Transplantation (methods), Humans, Male, Middle Aged, Primary Myelofibrosis (therapy), Transplantation Conditioning (methods), Treatment Outcome, Unrelated Donors.
- MESH :
- adverse effects : Cord Blood Stem Cell Transplantation.
- methods : Cord Blood Stem Cell Transplantation, Hematopoietic Stem Cell Transplantation, Transplantation Conditioning.
- therapy : Primary Myelofibrosis.
- Female, Fetal Blood, Humans, Male, Middle Aged, Treatment Outcome, Unrelated Donors.
Abstract
To determine whether umbilical cord blood transplantation (UCBT) is an alternative cure for myelofibrosis (MF), we evaluated 35 UCBTs reported to Eurocord. Seven patients had secondary acute myeloid leukemia (AML) at UCBT, and median age at UCBT was 54 years. Twenty-four patients received a reduced-intensity conditioning (RIC) regimen, and 17 of 35 patients received total body irradiation (2 to 12 Gy)-fludarabine-cyclophosphamide (TCF) conditioning. The median follow-up was 24 months. The cumulative incidence of neutrophil recovery at 60 days was 80%. Fifteen patients relapsed after UCBT. The 2-year overall survival and event-free-survival (EFS) rates were 44% and 30%, respectively. All patients given TCF achieved neutrophil and platelet recovery, and the use of TCF was associated with superior EFS in the RIC population (44% versus 0%, P = .001). Patients with transformation to AML had similar outcomes to patients with less advanced stages. In conclusion, despite graft failure remaining a major concern, the role of UCBT in the management of MF, especially using RIC TCF-based regimens, deserves further investigation to improve results.
DOI: 10.1016/j.bbmt.2014.06.011
PubMed: 24946719
Links to Exploration step
pubmed:24946719Le document en format XML
<record><TEI><teiHeader><fileDesc><titleStmt><title xml:lang="en">Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis.</title><author><name sortKey="Robin, Marie" sort="Robin, Marie" uniqKey="Robin M" first="Marie" last="Robin">Marie Robin</name><affiliation><nlm:affiliation>Hematology-Bone Marrow Transplantation, Saint-Louis Hospital, Paris, France. Electronic address: marie.robin@paris7.jussieu.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Giannotti, Federica" sort="Giannotti, Federica" uniqKey="Giannotti F" first="Federica" last="Giannotti">Federica Giannotti</name><affiliation><nlm:affiliation>Eurocord International Registry, Hôpital Saint-Louis, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Deconinck, Eric" sort="Deconinck, Eric" uniqKey="Deconinck E" first="Eric" last="Deconinck">Eric Deconinck</name><affiliation><nlm:affiliation>Service d'Hématologie, CHU de Besançon, INSERM U-645, Université de Franche-Comté, Besançon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Mohty, Mohamad" sort="Mohty, Mohamad" uniqKey="Mohty M" first="Mohamad" last="Mohty">Mohamad Mohty</name><affiliation><nlm:affiliation>Hematologie, CHU Saint-Antoine, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Michallet, Mauricette" sort="Michallet, Mauricette" uniqKey="Michallet M" first="Mauricette" last="Michallet">Mauricette Michallet</name><affiliation><nlm:affiliation>Hematology Department 1G, Centre Hospitalier Lyon Sud, Pierre Benite, France.</nlm:affiliation></affiliation></author><author><name sortKey="Sanz, Guillermo" sort="Sanz, Guillermo" uniqKey="Sanz G" first="Guillermo" last="Sanz">Guillermo Sanz</name><affiliation><nlm:affiliation>Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Chevallier, Patrice" sort="Chevallier, Patrice" uniqKey="Chevallier P" first="Patrice" last="Chevallier">Patrice Chevallier</name><affiliation><nlm:affiliation>Hematology, Nantes University Hospital, Nantes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Cahn, Jean Yves" sort="Cahn, Jean Yves" uniqKey="Cahn J" first="Jean-Yves" last="Cahn">Jean-Yves Cahn</name><affiliation><nlm:affiliation>Department of Hematology, University Hospital, Grenoble, France.</nlm:affiliation></affiliation></author><author><name sortKey="Legrand, Faezeh" sort="Legrand, Faezeh" uniqKey="Legrand F" first="Faezeh" last="Legrand">Faezeh Legrand</name><affiliation><nlm:affiliation>Hematology, Nice University Hospital, Nice, France.</nlm:affiliation></affiliation></author><author><name sortKey="Rovira, Montserrat" sort="Rovira, Montserrat" uniqKey="Rovira M" first="Montserrat" last="Rovira">Montserrat Rovira</name><affiliation><nlm:affiliation>Hematology, Hospital Clínic, IDIBAPS, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Passweg, Jakob" sort="Passweg, Jakob" uniqKey="Passweg J" first="Jakob" last="Passweg">Jakob Passweg</name><affiliation><nlm:affiliation>Hematology Department, Basel University Hospital, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Sierra, Jorge" sort="Sierra, Jorge" uniqKey="Sierra J" first="Jorge" last="Sierra">Jorge Sierra</name><affiliation><nlm:affiliation>Clinical Hematology, Hospital De Sant Pau, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Nguyen, Stephanie" sort="Nguyen, Stephanie" uniqKey="Nguyen S" first="Stephanie" last="Nguyen">Stephanie Nguyen</name><affiliation><nlm:affiliation>Hematology, Hôpital Pitié-Salpêtrière, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Maillard, Natacha" sort="Maillard, Natacha" uniqKey="Maillard N" first="Natacha" last="Maillard">Natacha Maillard</name><affiliation><nlm:affiliation>CHU Hematology, Poitiers, France.</nlm:affiliation></affiliation></author><author><name sortKey="Yakoub Agha, Ibrahim" sort="Yakoub Agha, Ibrahim" uniqKey="Yakoub Agha I" first="Ibrahim" last="Yakoub-Agha">Ibrahim Yakoub-Agha</name><affiliation><nlm:affiliation>Hematology, CHRU de Lille, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Linkesch, Werner" sort="Linkesch, Werner" uniqKey="Linkesch W" first="Werner" last="Linkesch">Werner Linkesch</name><affiliation><nlm:affiliation>Medical University Graz, Graz, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Cannell, Paul" sort="Cannell, Paul" uniqKey="Cannell P" first="Paul" last="Cannell">Paul Cannell</name><affiliation><nlm:affiliation>Hematology, Royal Perth Hospital, Perth, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Marcatti, Magda" sort="Marcatti, Magda" uniqKey="Marcatti M" first="Magda" last="Marcatti">Magda Marcatti</name><affiliation><nlm:affiliation>Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Bay, Jacques Olivier" sort="Bay, Jacques Olivier" uniqKey="Bay J" first="Jacques-Olivier" last="Bay">Jacques-Olivier Bay</name><affiliation><nlm:affiliation>Service de Thérapie Cellulaire et d'Hématologie Clinique Adulte, Hotel-Dieu, Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Chalandon, Yves" sort="Chalandon, Yves" uniqKey="Chalandon Y" first="Yves" last="Chalandon">Yves Chalandon</name><affiliation><nlm:affiliation>Hôpitaux universitaires de Genève, Suisse.</nlm:affiliation></affiliation></author><author><name sortKey="Kroger, Nicolaus" sort="Kroger, Nicolaus" uniqKey="Kroger N" first="Nicolaus" last="Kröger">Nicolaus Kröger</name><affiliation><nlm:affiliation>University Medical Center Hamburg-Eppendorf Center of Oncology, Department of Stem Cell Transplantation, Chairman of the CMWP EBMT, Hamburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Gluckman, Eliane" sort="Gluckman, Eliane" uniqKey="Gluckman E" first="Eliane" last="Gluckman">Eliane Gluckman</name><affiliation><nlm:affiliation>Eurocord International Registry, Hôpital Saint-Louis, Paris, France; Monacord, Centre scientifique de Monaco, Monaco.</nlm:affiliation></affiliation></author><author><name sortKey="Rocha, Vanderson" sort="Rocha, Vanderson" uniqKey="Rocha V" first="Vanderson" last="Rocha">Vanderson Rocha</name><affiliation><nlm:affiliation>Eurocord International Registry, Hôpital Saint-Louis, Paris, France; Department of Clinical Haematology, Bone Marrow Transplant Unit, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Olavarria, Eduardo" sort="Olavarria, Eduardo" uniqKey="Olavarria E" first="Eduardo" last="Olavarria">Eduardo Olavarria</name><affiliation><nlm:affiliation>Hospital de Navarra, Chairman of MPN Subcommittee of the CMWP-EBMT, Pamplona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Ruggeri, Annalisa" sort="Ruggeri, Annalisa" uniqKey="Ruggeri A" first="Annalisa" last="Ruggeri">Annalisa Ruggeri</name><affiliation><nlm:affiliation>Eurocord International Registry, Hôpital Saint-Louis, Paris, France; Hematologie, CHU Saint-Antoine, Paris, France.</nlm:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">PubMed</idno><date when="2014">2014</date><idno type="RBID">pubmed:24946719</idno><idno type="pmid">24946719</idno><idno type="doi">10.1016/j.bbmt.2014.06.011</idno><idno type="wicri:Area/PubMed/Corpus">003360</idno><idno type="wicri:explorRef" wicri:stream="PubMed" wicri:step="Corpus" wicri:corpus="PubMed">003360</idno></publicationStmt><sourceDesc><biblStruct><analytic><title xml:lang="en">Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis.</title><author><name sortKey="Robin, Marie" sort="Robin, Marie" uniqKey="Robin M" first="Marie" last="Robin">Marie Robin</name><affiliation><nlm:affiliation>Hematology-Bone Marrow Transplantation, Saint-Louis Hospital, Paris, France. Electronic address: marie.robin@paris7.jussieu.fr.</nlm:affiliation></affiliation></author><author><name sortKey="Giannotti, Federica" sort="Giannotti, Federica" uniqKey="Giannotti F" first="Federica" last="Giannotti">Federica Giannotti</name><affiliation><nlm:affiliation>Eurocord International Registry, Hôpital Saint-Louis, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Deconinck, Eric" sort="Deconinck, Eric" uniqKey="Deconinck E" first="Eric" last="Deconinck">Eric Deconinck</name><affiliation><nlm:affiliation>Service d'Hématologie, CHU de Besançon, INSERM U-645, Université de Franche-Comté, Besançon, France.</nlm:affiliation></affiliation></author><author><name sortKey="Mohty, Mohamad" sort="Mohty, Mohamad" uniqKey="Mohty M" first="Mohamad" last="Mohty">Mohamad Mohty</name><affiliation><nlm:affiliation>Hematologie, CHU Saint-Antoine, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Michallet, Mauricette" sort="Michallet, Mauricette" uniqKey="Michallet M" first="Mauricette" last="Michallet">Mauricette Michallet</name><affiliation><nlm:affiliation>Hematology Department 1G, Centre Hospitalier Lyon Sud, Pierre Benite, France.</nlm:affiliation></affiliation></author><author><name sortKey="Sanz, Guillermo" sort="Sanz, Guillermo" uniqKey="Sanz G" first="Guillermo" last="Sanz">Guillermo Sanz</name><affiliation><nlm:affiliation>Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Chevallier, Patrice" sort="Chevallier, Patrice" uniqKey="Chevallier P" first="Patrice" last="Chevallier">Patrice Chevallier</name><affiliation><nlm:affiliation>Hematology, Nantes University Hospital, Nantes, France.</nlm:affiliation></affiliation></author><author><name sortKey="Cahn, Jean Yves" sort="Cahn, Jean Yves" uniqKey="Cahn J" first="Jean-Yves" last="Cahn">Jean-Yves Cahn</name><affiliation><nlm:affiliation>Department of Hematology, University Hospital, Grenoble, France.</nlm:affiliation></affiliation></author><author><name sortKey="Legrand, Faezeh" sort="Legrand, Faezeh" uniqKey="Legrand F" first="Faezeh" last="Legrand">Faezeh Legrand</name><affiliation><nlm:affiliation>Hematology, Nice University Hospital, Nice, France.</nlm:affiliation></affiliation></author><author><name sortKey="Rovira, Montserrat" sort="Rovira, Montserrat" uniqKey="Rovira M" first="Montserrat" last="Rovira">Montserrat Rovira</name><affiliation><nlm:affiliation>Hematology, Hospital Clínic, IDIBAPS, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Passweg, Jakob" sort="Passweg, Jakob" uniqKey="Passweg J" first="Jakob" last="Passweg">Jakob Passweg</name><affiliation><nlm:affiliation>Hematology Department, Basel University Hospital, Basel, Switzerland.</nlm:affiliation></affiliation></author><author><name sortKey="Sierra, Jorge" sort="Sierra, Jorge" uniqKey="Sierra J" first="Jorge" last="Sierra">Jorge Sierra</name><affiliation><nlm:affiliation>Clinical Hematology, Hospital De Sant Pau, Barcelona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Nguyen, Stephanie" sort="Nguyen, Stephanie" uniqKey="Nguyen S" first="Stephanie" last="Nguyen">Stephanie Nguyen</name><affiliation><nlm:affiliation>Hematology, Hôpital Pitié-Salpêtrière, Paris, France.</nlm:affiliation></affiliation></author><author><name sortKey="Maillard, Natacha" sort="Maillard, Natacha" uniqKey="Maillard N" first="Natacha" last="Maillard">Natacha Maillard</name><affiliation><nlm:affiliation>CHU Hematology, Poitiers, France.</nlm:affiliation></affiliation></author><author><name sortKey="Yakoub Agha, Ibrahim" sort="Yakoub Agha, Ibrahim" uniqKey="Yakoub Agha I" first="Ibrahim" last="Yakoub-Agha">Ibrahim Yakoub-Agha</name><affiliation><nlm:affiliation>Hematology, CHRU de Lille, Lille, France.</nlm:affiliation></affiliation></author><author><name sortKey="Linkesch, Werner" sort="Linkesch, Werner" uniqKey="Linkesch W" first="Werner" last="Linkesch">Werner Linkesch</name><affiliation><nlm:affiliation>Medical University Graz, Graz, Austria.</nlm:affiliation></affiliation></author><author><name sortKey="Cannell, Paul" sort="Cannell, Paul" uniqKey="Cannell P" first="Paul" last="Cannell">Paul Cannell</name><affiliation><nlm:affiliation>Hematology, Royal Perth Hospital, Perth, Australia.</nlm:affiliation></affiliation></author><author><name sortKey="Marcatti, Magda" sort="Marcatti, Magda" uniqKey="Marcatti M" first="Magda" last="Marcatti">Magda Marcatti</name><affiliation><nlm:affiliation>Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy.</nlm:affiliation></affiliation></author><author><name sortKey="Bay, Jacques Olivier" sort="Bay, Jacques Olivier" uniqKey="Bay J" first="Jacques-Olivier" last="Bay">Jacques-Olivier Bay</name><affiliation><nlm:affiliation>Service de Thérapie Cellulaire et d'Hématologie Clinique Adulte, Hotel-Dieu, Clermont-Ferrand, France.</nlm:affiliation></affiliation></author><author><name sortKey="Chalandon, Yves" sort="Chalandon, Yves" uniqKey="Chalandon Y" first="Yves" last="Chalandon">Yves Chalandon</name><affiliation><nlm:affiliation>Hôpitaux universitaires de Genève, Suisse.</nlm:affiliation></affiliation></author><author><name sortKey="Kroger, Nicolaus" sort="Kroger, Nicolaus" uniqKey="Kroger N" first="Nicolaus" last="Kröger">Nicolaus Kröger</name><affiliation><nlm:affiliation>University Medical Center Hamburg-Eppendorf Center of Oncology, Department of Stem Cell Transplantation, Chairman of the CMWP EBMT, Hamburg, Germany.</nlm:affiliation></affiliation></author><author><name sortKey="Gluckman, Eliane" sort="Gluckman, Eliane" uniqKey="Gluckman E" first="Eliane" last="Gluckman">Eliane Gluckman</name><affiliation><nlm:affiliation>Eurocord International Registry, Hôpital Saint-Louis, Paris, France; Monacord, Centre scientifique de Monaco, Monaco.</nlm:affiliation></affiliation></author><author><name sortKey="Rocha, Vanderson" sort="Rocha, Vanderson" uniqKey="Rocha V" first="Vanderson" last="Rocha">Vanderson Rocha</name><affiliation><nlm:affiliation>Eurocord International Registry, Hôpital Saint-Louis, Paris, France; Department of Clinical Haematology, Bone Marrow Transplant Unit, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.</nlm:affiliation></affiliation></author><author><name sortKey="Olavarria, Eduardo" sort="Olavarria, Eduardo" uniqKey="Olavarria E" first="Eduardo" last="Olavarria">Eduardo Olavarria</name><affiliation><nlm:affiliation>Hospital de Navarra, Chairman of MPN Subcommittee of the CMWP-EBMT, Pamplona, Spain.</nlm:affiliation></affiliation></author><author><name sortKey="Ruggeri, Annalisa" sort="Ruggeri, Annalisa" uniqKey="Ruggeri A" first="Annalisa" last="Ruggeri">Annalisa Ruggeri</name><affiliation><nlm:affiliation>Eurocord International Registry, Hôpital Saint-Louis, Paris, France; Hematologie, CHU Saint-Antoine, Paris, France.</nlm:affiliation></affiliation></author></analytic><series><title level="j">Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</title><idno type="eISSN">1523-6536</idno><imprint><date when="2014" type="published">2014</date></imprint></series></biblStruct></sourceDesc></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Cord Blood Stem Cell Transplantation (adverse effects)</term><term>Cord Blood Stem Cell Transplantation (methods)</term><term>Female</term><term>Fetal Blood</term><term>Hematopoietic Stem Cell Transplantation (methods)</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Primary Myelofibrosis (therapy)</term><term>Transplantation Conditioning (methods)</term><term>Treatment Outcome</term><term>Unrelated Donors</term></keywords><keywords scheme="MESH" qualifier="adverse effects" xml:lang="en"><term>Cord Blood Stem Cell Transplantation</term></keywords><keywords scheme="MESH" qualifier="methods" xml:lang="en"><term>Cord Blood Stem Cell Transplantation</term><term>Hematopoietic Stem Cell Transplantation</term><term>Transplantation Conditioning</term></keywords><keywords scheme="MESH" qualifier="therapy" xml:lang="en"><term>Primary Myelofibrosis</term></keywords><keywords scheme="MESH" xml:lang="en"><term>Female</term><term>Fetal Blood</term><term>Humans</term><term>Male</term><term>Middle Aged</term><term>Treatment Outcome</term><term>Unrelated Donors</term></keywords></textClass></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">To determine whether umbilical cord blood transplantation (UCBT) is an alternative cure for myelofibrosis (MF), we evaluated 35 UCBTs reported to Eurocord. Seven patients had secondary acute myeloid leukemia (AML) at UCBT, and median age at UCBT was 54 years. Twenty-four patients received a reduced-intensity conditioning (RIC) regimen, and 17 of 35 patients received total body irradiation (2 to 12 Gy)-fludarabine-cyclophosphamide (TCF) conditioning. The median follow-up was 24 months. The cumulative incidence of neutrophil recovery at 60 days was 80%. Fifteen patients relapsed after UCBT. The 2-year overall survival and event-free-survival (EFS) rates were 44% and 30%, respectively. All patients given TCF achieved neutrophil and platelet recovery, and the use of TCF was associated with superior EFS in the RIC population (44% versus 0%, P = .001). Patients with transformation to AML had similar outcomes to patients with less advanced stages. In conclusion, despite graft failure remaining a major concern, the role of UCBT in the management of MF, especially using RIC TCF-based regimens, deserves further investigation to improve results.</div></front></TEI><pubmed><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">24946719</PMID><DateCreated><Year>2014</Year><Month>10</Month><Day>11</Day></DateCreated><DateCompleted><Year>2015</Year><Month>06</Month><Day>22</Day></DateCompleted><DateRevised><Year>2014</Year><Month>10</Month><Day>11</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1523-6536</ISSN><JournalIssue CitedMedium="Internet"><Volume>20</Volume><Issue>11</Issue><PubDate><Year>2014</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation</Title><ISOAbbreviation>Biol. Blood Marrow Transplant.</ISOAbbreviation></Journal><ArticleTitle>Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis.</ArticleTitle><Pagination><MedlinePgn>1841-6</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.bbmt.2014.06.011</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S1083-8791(14)00361-9</ELocationID><Abstract><AbstractText>To determine whether umbilical cord blood transplantation (UCBT) is an alternative cure for myelofibrosis (MF), we evaluated 35 UCBTs reported to Eurocord. Seven patients had secondary acute myeloid leukemia (AML) at UCBT, and median age at UCBT was 54 years. Twenty-four patients received a reduced-intensity conditioning (RIC) regimen, and 17 of 35 patients received total body irradiation (2 to 12 Gy)-fludarabine-cyclophosphamide (TCF) conditioning. The median follow-up was 24 months. The cumulative incidence of neutrophil recovery at 60 days was 80%. Fifteen patients relapsed after UCBT. The 2-year overall survival and event-free-survival (EFS) rates were 44% and 30%, respectively. All patients given TCF achieved neutrophil and platelet recovery, and the use of TCF was associated with superior EFS in the RIC population (44% versus 0%, P = .001). Patients with transformation to AML had similar outcomes to patients with less advanced stages. In conclusion, despite graft failure remaining a major concern, the role of UCBT in the management of MF, especially using RIC TCF-based regimens, deserves further investigation to improve results.</AbstractText><CopyrightInformation>Copyright © 2014 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Robin</LastName><ForeName>Marie</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematology-Bone Marrow Transplantation, Saint-Louis Hospital, Paris, France. Electronic address: marie.robin@paris7.jussieu.fr.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Giannotti</LastName><ForeName>Federica</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Eurocord International Registry, Hôpital Saint-Louis, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Deconinck</LastName><ForeName>Eric</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Service d'Hématologie, CHU de Besançon, INSERM U-645, Université de Franche-Comté, Besançon, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Mohty</LastName><ForeName>Mohamad</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematologie, CHU Saint-Antoine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Michallet</LastName><ForeName>Mauricette</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematology Department 1G, Centre Hospitalier Lyon Sud, Pierre Benite, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanz</LastName><ForeName>Guillermo</ForeName><Initials>G</Initials><AffiliationInfo><Affiliation>Hematology Department, Hospital Universitario y Politécnico La Fe, Valencia, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chevallier</LastName><ForeName>Patrice</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hematology, Nantes University Hospital, Nantes, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cahn</LastName><ForeName>Jean-Yves</ForeName><Initials>JY</Initials><AffiliationInfo><Affiliation>Department of Hematology, University Hospital, Grenoble, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Legrand</LastName><ForeName>Faezeh</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Hematology, Nice University Hospital, Nice, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rovira</LastName><ForeName>Montserrat</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematology, Hospital Clínic, IDIBAPS, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Passweg</LastName><ForeName>Jakob</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Hematology Department, Basel University Hospital, Basel, Switzerland.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sierra</LastName><ForeName>Jorge</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Clinical Hematology, Hospital De Sant Pau, Barcelona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Nguyen</LastName><ForeName>Stephanie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Hematology, Hôpital Pitié-Salpêtrière, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Maillard</LastName><ForeName>Natacha</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>CHU Hematology, Poitiers, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Yakoub-Agha</LastName><ForeName>Ibrahim</ForeName><Initials>I</Initials><AffiliationInfo><Affiliation>Hematology, CHRU de Lille, Lille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Linkesch</LastName><ForeName>Werner</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Medical University Graz, Graz, Austria.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cannell</LastName><ForeName>Paul</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Hematology, Royal Perth Hospital, Perth, Australia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marcatti</LastName><ForeName>Magda</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>Hematology and Bone Marrow Transplantation Unit, San Raffaele Scientific Institute, Milan, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bay</LastName><ForeName>Jacques-Olivier</ForeName><Initials>JO</Initials><AffiliationInfo><Affiliation>Service de Thérapie Cellulaire et d'Hématologie Clinique Adulte, Hotel-Dieu, Clermont-Ferrand, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chalandon</LastName><ForeName>Yves</ForeName><Initials>Y</Initials><AffiliationInfo><Affiliation>Hôpitaux universitaires de Genève, Suisse.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Kröger</LastName><ForeName>Nicolaus</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>University Medical Center Hamburg-Eppendorf Center of Oncology, Department of Stem Cell Transplantation, Chairman of the CMWP EBMT, Hamburg, Germany.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gluckman</LastName><ForeName>Eliane</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Eurocord International Registry, Hôpital Saint-Louis, Paris, France; Monacord, Centre scientifique de Monaco, Monaco.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rocha</LastName><ForeName>Vanderson</ForeName><Initials>V</Initials><AffiliationInfo><Affiliation>Eurocord International Registry, Hôpital Saint-Louis, Paris, France; Department of Clinical Haematology, Bone Marrow Transplant Unit, Oxford University Hospitals NHS Trust, Oxford, United Kingdom.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Olavarria</LastName><ForeName>Eduardo</ForeName><Initials>E</Initials><AffiliationInfo><Affiliation>Hospital de Navarra, Chairman of MPN Subcommittee of the CMWP-EBMT, Pamplona, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ruggeri</LastName><ForeName>Annalisa</ForeName><Initials>A</Initials><AffiliationInfo><Affiliation>Eurocord International Registry, Hôpital Saint-Louis, Paris, France; Hematologie, CHU Saint-Antoine, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>Eurocord and Chronic Malignancies Working Party-European Group for Blood and Marrow Transplantation (CMWP-EBMT)</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2014</Year><Month>06</Month><Day>16</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Biol Blood Marrow Transplant</MedlineTA><NlmUniqueID>9600628</NlmUniqueID><ISSNLinking>1083-8791</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D036101" MajorTopicYN="N">Cord Blood Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000009" MajorTopicYN="N">adverse effects</QualifierName><QualifierName UI="Q000379" MajorTopicYN="Y">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005312" MajorTopicYN="N">Fetal Blood</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018380" MajorTopicYN="N">Hematopoietic Stem Cell Transplantation</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D055728" MajorTopicYN="N">Primary Myelofibrosis</DescriptorName><QualifierName UI="Q000628" MajorTopicYN="Y">therapy</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D019172" MajorTopicYN="N">Transplantation Conditioning</DescriptorName><QualifierName UI="Q000379" MajorTopicYN="N">methods</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016896" MajorTopicYN="N">Treatment Outcome</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D061349" MajorTopicYN="N">Unrelated Donors</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">Myelofibrosis</Keyword><Keyword MajorTopicYN="N">Umbilical cord blood transplantation</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2014</Year><Month>05</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2014</Year><Month>06</Month><Day>10</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2014</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2014</Year><Month>6</Month><Day>21</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2015</Year><Month>6</Month><Day>24</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">24946719</ArticleId><ArticleId IdType="pii">S1083-8791(14)00361-9</ArticleId><ArticleId IdType="doi">10.1016/j.bbmt.2014.06.011</ArticleId></ArticleIdList></PubmedData></pubmed></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Asie/explor/AustralieFrV1/Data/PubMed/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 003360 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd -nk 003360 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Asie
|area= AustralieFrV1
|flux= PubMed
|étape= Corpus
|type= RBID
|clé= pubmed:24946719
|texte= Unrelated cord blood transplantation for patients with primary or secondary myelofibrosis.
}}
Pour générer des pages wiki
HfdIndexSelect -h $EXPLOR_AREA/Data/PubMed/Corpus/RBID.i -Sk "pubmed:24946719" \
| HfdSelect -Kh $EXPLOR_AREA/Data/PubMed/Corpus/biblio.hfd \
| NlmPubMed2Wicri -a AustralieFrV1
| This area was generated with Dilib version V0.6.33. |  |